论文部分内容阅读
目的观察Graves病(GD)患者131I治疗后促甲状腺激素受体抗体(TRAb)动态变化,并分析其与早发甲减的相关性。方法131I治疗的240例初诊GD患者,分为早发甲减组(n=134)和非早发甲减组(n=106),测定131I治疗前及治疗后3、6、12个月时TRAb浓度。结果两组患者TRAb浓度在131I治疗后3个月升高,6个月时达到高峰,至12个月时降至治疗前水平;早发甲减组患者131I治疗后6个月TRAb高于非早发甲减组(F=13.967,P<0.01)。结论 GD患者131I治疗后1年内TRAb呈现一过性升高,其与早发甲减密切相关,TRAb动态变化对早期判断GD131I治疗预后具有重要的临床价值。
Objective To observe the dynamic changes of thyroid stimulating hormone receptor antibody (TRAb) in patients with Graves’ disease (GD) after 131I treatment and analyze its correlation with early hypothyroidism. Methods A total of 240 newly diagnosed GD patients treated with 131I were divided into two groups: early hypothyroidism (n = 134) and non-early hypothyroidism (n = 106) TRAb concentration. Results TRAb concentrations in both groups increased at 3 months after 131I treatment, peaked at 6 months, and dropped to pre-treatment levels at 12 months. TRAb was higher at 6 months after 131I treatment in patients with early-onset hypothyroidism than in non- Early hypothyroidism group (F = 13.967, P <0.01). Conclusion The TRAb in patients with GD has a transient increase within one year after 131I treatment, which is associated with early hypothyroidism and close reduction. The dynamic changes of TRAb have important clinical value in judging the prognosis of GD131I in the early stage.